Cassava Sciences Inc (SAVA)
25.75
-0.46
(-1.76%)
USD |
NASDAQ |
Nov 04, 13:03
Cassava Sciences Net Income (Quarterly): 6.155M for June 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 6.155M |
| March 31, 2024 | 25.04M |
| December 31, 2023 | -20.92M |
| September 30, 2023 | -25.65M |
| June 30, 2023 | -26.38M |
| March 31, 2023 | -24.27M |
| December 31, 2022 | -19.13M |
| September 30, 2022 | -20.26M |
| June 30, 2022 | -19.33M |
| March 31, 2022 | -17.53M |
| December 31, 2021 | -14.17M |
| September 30, 2021 | -9.562M |
| June 30, 2021 | -5.125M |
| March 31, 2021 | -3.526M |
| December 31, 2020 | -2.618M |
| September 30, 2020 | -1.43M |
| June 30, 2020 | -1.136M |
| March 31, 2020 | -1.15M |
| December 31, 2019 | -1.516M |
| September 30, 2019 | -0.697M |
| June 30, 2019 | -1.059M |
| March 31, 2019 | -1.359M |
| December 31, 2018 | -0.677M |
| September 30, 2018 | -1.267M |
| June 30, 2018 | -2.452M |
| Date | Value |
|---|---|
| March 31, 2018 | -2.16M |
| December 31, 2017 | -2.418M |
| September 30, 2017 | -2.59M |
| June 30, 2017 | -4.16M |
| March 31, 2017 | -2.743M |
| December 31, 2016 | -2.522M |
| September 30, 2016 | -3.518M |
| June 30, 2016 | -3.015M |
| March 31, 2016 | -5.795M |
| December 31, 2015 | -4.517M |
| September 30, 2015 | -3.671M |
| June 30, 2015 | -3.374M |
| March 31, 2015 | -2.583M |
| December 31, 2014 | -2.156M |
| September 30, 2014 | -3.534M |
| June 30, 2014 | -3.246M |
| March 31, 2014 | -3.45M |
| December 31, 2013 | 33.02M |
| September 30, 2013 | -0.762M |
| June 30, 2013 | -0.301M |
| March 31, 2013 | -0.408M |
| December 31, 2012 | -1.794M |
| September 30, 2012 | -1.55M |
| June 30, 2012 | -0.13M |
| March 31, 2012 | 0.03M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-26.38M
Minimum
Jun 2023
25.04M
Maximum
Mar 2024
-9.605M
Average
-9.562M
Median
Sep 2021
Net Income (Quarterly) Benchmarks
| Bristol-Myers Squibb Co | 1.211B |
| Eli Lilly and Co | 970.30M |
| Seelos Therapeutics Inc | 1.71M |
| Biomarin Pharmaceutical Inc | 106.08M |
| EyePoint Pharmaceuticals Inc | -30.83M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 61.40M |
| EPS Diluted (Quarterly) | 0.13 |
| Enterprise Value | 1.050B |
| Earnings Yield | -5.48% |
| Operating Earnings Yield | 2.79% |
| Normalized Earnings Yield | 18.49 |